Progyny, Inc. (NASDAQ:PGNY) Shares Bought by Edgestream Partners L.P.

Edgestream Partners L.P. increased its holdings in Progyny, Inc. (NASDAQ:PGNY) by 170.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 186,588 shares of the company’s stock after acquiring an additional 117,506 shares during the quarter. Edgestream Partners L.P. owned approximately 0.22% of Progyny worth $3,219,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Victory Capital Management Inc. raised its position in shares of Progyny by 79.4% in the 4th quarter. Victory Capital Management Inc. now owns 203,277 shares of the company’s stock valued at $3,507,000 after purchasing an additional 89,941 shares in the last quarter. SBI Securities Co. Ltd. acquired a new stake in Progyny in the fourth quarter valued at $74,000. Acuitas Investments LLC bought a new position in Progyny during the 4th quarter valued at $2,980,000. Baillie Gifford & Co. grew its holdings in Progyny by 52.2% during the 4th quarter. Baillie Gifford & Co. now owns 1,332,690 shares of the company’s stock worth $22,989,000 after acquiring an additional 456,853 shares in the last quarter. Finally, Entropy Technologies LP increased its position in shares of Progyny by 5.5% in the 4th quarter. Entropy Technologies LP now owns 47,883 shares of the company’s stock worth $826,000 after purchasing an additional 2,499 shares during the last quarter. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on PGNY shares. Canaccord Genuity Group increased their price target on shares of Progyny from $17.00 to $23.00 and gave the stock a “hold” rating in a research report on Friday, February 28th. Bank of America increased their target price on Progyny from $21.00 to $25.00 and gave the stock a “buy” rating in a report on Tuesday, February 11th. JPMorgan Chase & Co. boosted their price target on Progyny from $17.00 to $23.00 and gave the company a “neutral” rating in a report on Tuesday, January 28th. Barclays reduced their price objective on Progyny from $30.00 to $17.00 and set an “overweight” rating on the stock in a research note on Thursday, November 14th. Finally, Truist Financial reaffirmed a “hold” rating and issued a $19.00 price objective (down previously from $26.00) on shares of Progyny in a report on Wednesday, November 13th. Nine investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $24.82.

Progyny Stock Performance

Shares of PGNY opened at $20.80 on Friday. Progyny, Inc. has a 1 year low of $13.39 and a 1 year high of $38.98. The firm has a fifty day moving average of $21.32 and a 200-day moving average of $18.69. The company has a market cap of $1.77 billion, a price-to-earnings ratio of 35.86, a price-to-earnings-growth ratio of 2.39 and a beta of 1.41.

Insider Buying and Selling at Progyny

In other Progyny news, Chairman David J. Schlanger bought 150,000 shares of the stock in a transaction that occurred on Thursday, December 26th. The shares were purchased at an average cost of $14.68 per share, for a total transaction of $2,202,000.00. Following the transaction, the chairman now directly owns 228,269 shares in the company, valued at $3,350,988.92. The trade was a 191.65 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Peter Anevski bought 209,500 shares of the business’s stock in a transaction on Monday, December 23rd. The shares were acquired at an average cost of $14.48 per share, for a total transaction of $3,033,560.00. Following the purchase, the chief executive officer now directly owns 441,463 shares in the company, valued at $6,392,384.24. This represents a 90.32 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 12.30% of the stock is currently owned by company insiders.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.